NeoGenomics(NASDAQ) NEO

NeoGenomics tests patient samples to find specific cancer markers. It helps doctors choose the best treatments for their patients. These specialized lab services support many clinics and hospitals.

A Specialized Oncology Menu

• Molecular Testing: Analysis of DNA and RNA to find genetic changes, including next-generation sequencing (NGS) panels for solid tumors and blood cancers.
• Molecular Residual Disease: High-sensitivity assays designed to detect tiny amounts of cancer cells that remain after a patient receives treatment.
• Cytogenetics and FISH: Study of chromosomes and specific DNA sequences using fluorescence in-situ hybridization (FISH) to identify structural changes in diseased cells.
• Flow Cytometry: Measurement of cell population characteristics in blood or bone marrow to identify abnormal or malignant cell populations.
• Morphologic Analysis: Microscopic examination of cells by pathologists to provide initial diagnoses or second opinions on difficult and complex cases.

Strategic Moves and Acquisitions

• Acquired Inivata in June 2021 to add liquid biopsy technology and the RaDaR assay for detecting cancer recurrence.
• Expanded operations into the United Kingdom by opening a sample-processing laboratory in Cambridge.
• Acquired Pathline to increase the scale of its technical and professional component testing services.
• Launched the PanTracer portfolio and Neo Comprehensive panels to provide broader genomic information from limited patient samples.

Why Medical Professionals Choose NeoGenomics

The company maintains specialized laboratories across the United States and the United Kingdom. These facilities carry College of American Pathologists (CAP) accreditation and Clinical Laboratory Improvement Amendments (CLIA) certification.

This infrastructure allows local doctors to access advanced genetic tests. They can obtain complex results without buying expensive equipment or hiring extra staff.

A Snapshot of Recent Performance

• Revenue reached $201.7 million for the three-month period ended June 30, 2026, up 11.2% year over year.
• Gross profit was $91.9 million for the three-month period ended June 30, 2026, up 18.9% year over year.
• Net income was $2.2 million for the three-month period ended June 30, 2026, compared to a net loss of $45.1 million in the prior-year period.
• Cash and cash equivalents totaled $145.5 million as of June 30, 2026.

Evolution Toward Precision Medicine

NeoGenomics has transitioned from a traditional testing lab into a provider of advanced genomic data and precision medicine tools. Its focus on community healthcare settings supports personalized cancer treatment for a broad patient base.